✅ What is true (or at least what is being claimed now)

• Russian health authorities announced that Enteromix, an mRNA-based (or oncolytic + mRNA) vaccine developed in Russia, has completed preclinical testing and reportedly entered early human trials with about 48 volunteers. Moneycontrol+2The Tribune+2

• Media coverage of the announcement reports that for those initial participants there was tumor shrinkage (or slowed growth), and that no “serious side effects” were reported. Moneycontrol+2The Tribune+2

• The vaccine is described as “personalized”: designed based on each patient’s tumor genetics — a modern, promising approach in cancer immunotherapy. The Tribune+2The Economic Times+2

⚠️ What is not (yet) proven — and why many experts are skeptical

• The “100% effectiveness” claim refers to these very early results (preclinical + Phase I) — not large, robust, peer-reviewed clinical trials. AFP Fact Check+2reflections.live+2

• Independent scrutiny (fact-checks) notes there is no publicly available peer-reviewed data demonstrating that Enteromix reliably “cures” cancer or works across different cancers. AFP Fact Check+1

• Even Russian officials reportedly said the preclinical results showed tumor reduction or slowed growth — e.g. “reducing tumour size and slowing tumour growth … by 60-80%,” rather than complete cures. AFP Fact Check+2The Times of India+2

• Cancer is not a single disease but many — a vaccine effective for e.g. colorectal cancer may not work for other types. The announcements themselves say Enteromix’s first version targets colorectal cancer. The Tribune+2Business Standard+2

• Experts emphasize that large-scale, multi-phase clinical trials — normally involving hundreds to thousands of patients over years — are essential before concluding a “cure” or broadly effective therapy. AFP Fact Check+2reflections.live+2

🧪 Why this matters in medical science

• Early-stage results (Phase I / preclinical) often look more promising than how a treatment performs later; many treatments that looked great in Phase I ended up failing in later phases.

• A “vaccine” for cancer is more complicated than for infectious disease: cancers vary a lot between patients and tumour types; personalized vaccines could help, but they also raise challenges (genetic profiling, manufacturing, regulatory review, long-term safety).

• Without transparent clinical data (published in peer-reviewed journals), external scientists cannot independently verify the claims.

🎯 Conclusion: treat the “100%” claim as a hopeful but unverified announcement

It’s not “false” in the sense that there are real efforts and early trials with optimistic results. But the “100% effectiveness” — especially if interpreted as “cures cancer for all patients” — is not supported by robust scientific evidence at this time.

If you like, I can check all publicly available scientific data about Enteromix (preclinical & clinical) right now — that way you see exactly how far it has gone (and what remains unknown).